Dr. Stacy R. Smith, M.D.
Dermatology (Dermatology Physician)
561 Saxony Pl, Suite 102
Encinitas, CA 92024
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1989, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license G65407 (first issued 1989; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 38 payments worth $90,862 in total to this clinician.
| Lilly USA, LLC | $43,008 |
|---|---|
| Krystal Biotech Inc | $21,775 |
| AbbVie Inc. | $16,924 |
| Janssen Biotech, Inc. | $9,115 |
| Urgo Medical North America, LLC | $39.92 |
| Compensation for services other than consulting (speaking, faculty) | $65,100 |
|---|---|
| Consulting Fee | $23,950 |
| Travel and Lodging | $1,298 |
| Food and Beverage | $514 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Krystal Biotech Inc Aug 6, 2025 | Consulting Fee | $20,800 |
| Janssen Biotech, Inc. Mar 29, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| AbbVie Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,625 |
| AbbVie Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,625 |
| AbbVie Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,625 |
| AbbVie Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,625 |
| Lilly USA, LLC Feb 7, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC May 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC May 12, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| Lilly USA, LLC Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology | $1,200 |
| Krystal Biotech Inc Oct 27, 2025 | Consulting Fee | $975 |
| AbbVie Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,625 |
| AbbVie Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,625 |
| Krystal Biotech Inc Aug 6, 2025 | Consulting Fee | $20,800 |
| Janssen Biotech, Inc. Jul 26, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,350 |
| Lilly USA, LLC Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,800 |
| AbbVie Inc. Jun 23, 2025 | Consulting Fee | $2,175 |
| Lilly USA, LLC May 30, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| AbbVie Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,625 |
| Lilly USA, LLC May 12, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC May 12, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC May 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC May 9, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC May 7, 2025 | Travel and Lodging travel to COSTA MESA, CA · in-kind | $803 |
| Lilly USA, LLC May 6, 2025 | Travel and Lodging travel to CHULA VISTA, CA · in-kind | $495 |
| AbbVie Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,625 |
| Janssen Biotech, Inc. Mar 29, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| Janssen Biotech, Inc. Mar 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| Lilly USA, LLC Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Mar 3, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,600 |
| Lilly USA, LLC Feb 7, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,200 |
| Lilly USA, LLC Feb 7, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 6 companies. The companies reported $597,550 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A phase 3 randomized withdrawal and doseup titration multicenter extension study investigating the safety efficacy and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo
Pfizer Inc. - A phase 3 external and synthetic placebocontrolled randomized study with doseup for nonresponders to investigate safety and efficacy of ritlecitinib 50 mg and 100 mg once daily in adult and adolescent participants 12 …
Pfizer Inc. - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC - Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affec…
Janssen Research & Development, LLC - A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
Sun Pharmaceutical Industries Inc. - A phase 4, multicenter, open-label, single-arm study to investigate the efficacy of lebrikizumab in adult and adolescent participants with atopic dermatitis with limited body surface area involvement and high itch bur…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.